Health
Clover Biopharmaceuticals Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate – Press Release – Digital Journal
Joshua Liang, Chief Executive Officer of Clover Biopharmaceuticals, said, “We are excited to share these important preclinical results showing that our S-Trimer COVID-19 vaccine candidate induces immune protection against SARS-CoV-2, and we are also pleased w…
CHENGDU, China–(Business Wire)–Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on discovering and developing transformative biologic therapies and vaccines, today announced positive preclinical data demonstrating that its protein-based COVID-19 S-Trimer vaccine candidate in combination with adjuvants from either GSK (London Stock Exchange: GSK) or Dynavax (Nasdaq: DVAX) induces a strong immune response and protection against SARS-CoV-2 in animal models. The man…
-
Business18 hours agoBell Potter names the best ASX tech stocks to buy in FY 2026
-
Business23 hours ago2 excellent ASX ETFs I think have great potential to beat the ASX 200
-
General15 hours agoHuman remains located, police make arrest in search for Sunbury man Joshua Bishop
-
Noosa News22 hours agoTownsville remembers Jennifer Board, four years on from tragic death